1-chloro-3-isopentylbenzene | 1591938-86-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 1-chloro-3-isopentylbenzene
• 英文别名: 1-Chloro-3-(3-methylbutyl)benzene
• CAS: 1591938-86-1
• 化学式: C₁₁H₁₅Cl
• 分子量: 182.693
• InChiKey: JRIPTFISENCJRO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5
• 重原子数：
  12
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.45
• 拓扑面积：
  0
• 氢给体数：
  0
• 氢受体数：
  0

反应信息

• 作为产物：
  描述：

  异丁基三苯基溴化膦 在 palladium on activated charcoal 、 potassium tert-butylate 、 氢气 作用下， 以 四氢呋喃 、 乙酸乙酯 、 甲苯 为溶剂， 反应 10.0h， 生成 1-chloro-3-isopentylbenzene
  参考文献：
  名称：

  分析 Rh2(esp)2 催化的分子间 C-H 胺化反应中的位点选择性

  摘要：

  在涉及杂原子转移的 C-H 键氧化反应中预测位点选择性受到不同键类型之间小的能量差异以及影响反应性的空间和电子效应的微妙相互作用的挑战。在此，研究了控制异戊基苯衍生物的选择性 Rh2(esp)2 催化 C-H 胺化的因素，其中显示对氮源、氨基磺酸酯和底物的修饰会影响异构产物比率。线性回归数学模型用于定义一种关系，该关系将 IR 拉伸参数和 Hammett σ+ 值等同于苄基与叔 C-H 胺化的微分自由能。该模型为新型氨基磺酸酯的开发提供了依据，该酯可提供最高的苄基到叔位点选择性 (9.5:

  DOI：

  10.1021/ja5015508

文献信息

• WDR5 INHIBITORS AND MODULATORS
  申请人：Vanderbilt University

  公开号：US20180086767A1

  公开（公告）日：2018-03-29

  Described are compounds that disrupt the WDR5-MLL1 protein-protein interaction, pharmaceutical compositions including the compounds, and methods of using the compounds and compositions for treating disorders and conditions in a subject.

  描述了破坏WDR5-MLL1蛋白-蛋白相互作用的化合物，包括这些化合物的药物组合物，以及使用这些化合物和组合物治疗受试者疾病和症状的方法。
• [EN] ION CHANNEL INHIBITORY COMPOUNDS, PHARMACEUTICAL FORMULATIONS AND USES<br/>[FR] COMPOSÉS INHIBITEURS DE CANAUX IONIQUES, FORMULATIONS PHARMACEUTIQUES, ET UTILISATIONS
  申请人：AFASCI INC

  公开号：WO2017083867A1

  公开（公告）日：2017-05-18

  The present invention is directed towards new chemical entities which primarily inhibit the human T-type calcium channels and differentially modulate other key ion channels to control cell excitability, and abnormal neuronal activity particularly involved in the development and maintenance of persistent or chronic pain, and / or neurological disorders. These novel compounds are useful in the treatment and prevention of neurological and psychiatric disorders and diseases in which these ion channels are involved. The invention is also directed towards pharmaceutical formulations comprising these compounds and the uses of these compounds.

  本发明主要针对新的化学实体，其主要抑制人类T型钙通道，并差异调节其他关键离子通道，以控制细胞兴奋性，以及参与持续性或慢性疼痛的发展和维持，和/或神经系统疾病的异常神经元活动。这些新颖化合物对治疗和预防这些离子通道参与的神经和精神疾病和疾病具有用处。该发明还涉及包含这些化合物的药物配方以及这些化合物的用途。
• FUNGICIDAL COMPOSITIONS
  申请人：Haas Ulrich Johannes

  公开号：US20140335201A1

  公开（公告）日：2014-11-13

  The present invention provides a composition comprising a combination of components A) and B), wherein component A) is a compound of formula (I) and the component (B) is a further fungicide, insecticide or herbicide.

  本发明提供了一种组合物，包括组分A)和B)，其中组分A)是化合物的公式(I)，组分B)是另一种杀真菌剂、杀虫剂或除草剂。
• Heteroaryl fused aminoalkyl imidazole derivates: selective modulators of GABAA receptors
  申请人：DeSimone W. Robert

  公开号：US20060160842A1

  公开（公告）日：2006-07-20

  Disclosed are compounds of the formula: or the pharmaceutically acceptable non-toxic salts thereof wherein the A, B, C, D, X, R 1 , R 2 , R 3 , R 4 , R 5 , and R 6 , are variables defined herein, which compounds are highly selective agonists, antagonists or inverse agonists for GABAa brain receptors or prodrugs of agonists, antagonists or inverse agonists for GABAa brain receptors, and are therefore useful in the diagnosis and treatment of anxiety, Down Syndrome, sleep, cognitive and seizure disorders, depression, overdose with benzodiazepine drugs, and enhancement of memory and alertness.

  本发明揭示了以下式的化合物：或其药学上可接受的无毒盐，其中A、B、C、D、X、R1、R2、R3、R4、R5和R6是在此定义的变量，这些化合物是高度选择性的GABAa脑受体的激动剂、拮抗剂或反向激动剂，或者是GABAa脑受体的激动剂、拮抗剂或反向激动剂的前药，因此在焦虑、唐氏综合症、睡眠、认知和癫痫障碍、抑郁症、苯二氮卓类药物过量和增强记忆和警觉性的诊断和治疗中有用。
• N-HYDROXY-NAPHTHALENE DICARBOXAMIDE AND N-HYDROXY-BIPHENYL-DICARBOXAMIDE COMPOUNDS AS HISTONE DEACETYLASE INHIBITORS
  申请人：Kattar Solomon

  公开号：US20100216796A1

  公开（公告）日：2010-08-26

  The present invention relates to a novel class of N-hydroxy-naphthalene dicarboxamide and N-hydroxy-biphenyl-dicarboxamide derivatives. The N-hydroxy-naphthalene dicarboxamide and N-hydroxy-biphenyl-dicarboxamide compounds can be used to treat cancer. The N-hydroxy-naphthalene dicarboxamide and N-hydroxy-biphenyl-dicarboxamide compounds can also inhibit histone deacetylase and are suitable for use in selectively inducing terminal differentiation, and arresting cell growth and/or apoptosis of neoplastic cells, thereby inhibiting proliferation of such cells. Thus, the compounds of the present invention are useful in treating a patient having a tumor characterized by proliferation of neoplastic cells. The compounds of the invention may also be useful in the prevention and treatment of TRX-mediated diseases, such as autoimmune, allergic and inflammatory diseases, and in the prevention and/or treatment of diseases of the central nervous system (CNS), such as neurodegenerative diseases. The present invention further provides pharmaceutical compositions comprising the N-hydroxy-naphthalene dicarboxamide and N-hydroxy-biphenyl-dicarboxamide derivatives and safe dosing regimens of these pharmaceutical compositions, which are easy to follow, and which result in a therapeutically effective amount of the N-hydroxy-naphthalene dicarboxamide and N-hydroxy-biphenyl-dicarboxamide derivatives in vivo.

  本发明涉及一种新的N-羟基萘二甲酰胺和N-羟基联苯二甲酰胺衍生物。N-羟基萘二甲酰胺和N-羟基联苯二甲酰胺化合物可用于治疗癌症。N-羟基萘二甲酰胺和N-羟基联苯二甲酰胺化合物还可抑制组蛋白去乙酰化酶，并适用于选择性诱导末端分化，抑制肿瘤细胞的增殖和/或凋亡，从而抑制这些细胞的增殖。因此，本发明的化合物适用于治疗具有肿瘤细胞增殖特征的患者。本发明的化合物也可用于预防和治疗TRX介导的疾病，如自身免疫、过敏和炎症性疾病，以及中枢神经系统（CNS）疾病的预防和/或治疗，如神经退行性疾病。本发明还提供了包含N-羟基萘二甲酰胺和N-羟基联苯二甲酰胺衍生物的药物组合物和这些药物组合物的安全给药方案，易于遵循，并在体内产生治疗有效量的N-羟基萘二甲酰胺和N-羟基联苯二甲酰胺衍生物。